Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

BioCT Legislative Day 3/5/19 in Review

Connecticut’s bioscience industry has seen tremendous progress in recent years, and its key players say they want to work with lawmakers and other stakeholders to...

| By Kelley Gipson

BioCT welcomes Megan Rosengarten to Board

BioCT is pleased to welcome Megan Rosengarten to the BioCT Board of Directors. Megan is a proven leader known for commercializing new insights and opportunities, resulting in...

| By Kelley Gipson

Biohaven receives orphan status for MSA drug

Biohaven Pharmaceutical Holding Company has received orphan drug designation from the FDA for its product candidate verdiperstat (previously BHV-3241), a novel myeloperoxidase inhibitor, for the treatment of...

| By Kelley Gipson

Yale team ‘reengineers’ immune cells

Yale researchers have developed a new way to efficiently engineer immune cells, an advance which enhances the ability to fend off cancer and other diseases....